# Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)

> **NCT04997148** · — · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 116 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04997148
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-11
- **Primary completion:** 2023-09-14
- **Final completion:** 2023-09-14
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2024-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04997148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04997148, "Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04997148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*